Advance Research Of ARNi In Improving Myocardial Fibrosis

Sacubitril/Valsartan is associated with a further reduction in the risk of hospitalization and cardiovascular death in patients with heart failure with reduced ejection fraction(HFr EF).But the mechanism why Sacubitril/Valsartan benefits greater is not fully understood.A number of studies have shown that angiotesin receptor-neprilysin inhibitor(ARNI),as a novel mechanism of heart failure therapy,can inhibit the renin-angiotensin-aldosterone system(RAAS),and simultaneously inhibit natriuretic peptide degradatation which significantly improves cardiac remodeling and myocardial fibrosis,reduces ventricular arrhythmias,and further reduces the risk of cardiogenic death and sudden death compared with angiotensin converting enzyme inhibitor(ACEI).The mechanism may be related to the inhibition the over-activation of RASS,thereby inhibiting the expression of TGF-β,MMP-9 and other RAAS regulatory factors.